Immunoglobulin stability

In this issue of Biotechnology and Applied Biochemistry, I have had the opportunity to review the following article by Rajesh Parti and Samia Mankarious entitled “Stability assessment of lyophilized intravenous immunoglobulin after reconstitution in glass containers and poly(vinyl chloride) bags” (p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biotechnology and applied biochemistry 1997-02, Vol.25 (1), p.9-11
1. Verfasser: Sapan, Christine V.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this issue of Biotechnology and Applied Biochemistry, I have had the opportunity to review the following article by Rajesh Parti and Samia Mankarious entitled “Stability assessment of lyophilized intravenous immunoglobulin after reconstitution in glass containers and poly(vinyl chloride) bags” (pp. 13Ő18). This paper exemplifies the journal's Mission Statement as outlined by the Editor‐in‐Chief, Dr. Roger L Lundblad. As he expressed: “studies will be expected to address directly regulatory and clinical issues” and “issues impacting on the use of such macromolecules in therapeutics”. Over the last 20 years there have been a number of changes in technology which have accommodated modification in the delivery of therapeutic immune globulins. The intramuscular administration product was the hallmark of immune globulin application. However, the advent of intravenous infusion technology for immune globulins has expanded the usage and indication for these products. Many of these products are now provided in a liquid format which presents the manufacturer with a different set of parameters than for the lyophilized product, thus furthering the requirement for complex studies to address new objectives. Manufacturers of products, by they pharmaceutical or biopharmaceutical, are continually faced with issues associated with product stability and product compatibility. They are, at times, beyond the manufacturers' scope and need to be addressed at point of use. Therefore, the challenge remains in the hands of the clinician, the nurse and/or the pharmacist. As manufacturers, it is important to understand the ultimate practical usuage and application of products in a medical setting. With the advent of rapid changes in medical care and medical care delivery, the utilization may not be environmentally compatible or not always challenged through experimentation. If manufacturers explore compatibility of active ingredients, excipients and extractables, it is important that these findings be documented for wide‐spread distribution. This could be in the form of a publication such as the journal article and/or ultimately included as a package insert change or in a monograph. The authors, Parti and Mankarious, initiated their studies to address the importance of the intravenous immunoglobulin stability in the representative delivery care system. The study is complimented by the statistical significance of their data. The authors' approach could be used as a model for assessm
ISSN:0885-4513
1470-8744
DOI:10.1111/j.1470-8744.1997.tb00408.x